Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices

about

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices

Item

http://www.wikidata.org/entity/Q36469983

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices

@ast

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices

@en

type

Item

label

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices

@ast

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices

@en

prefLabel

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices

@ast

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices

@en

P1476

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices

@en

P2093

Maria Mehboob

http://www.w3.org/2001/XMLSchema#string

Osama Ishtiaq

http://www.w3.org/2001/XMLSchema#string

Sajjad Raza

http://www.w3.org/2001/XMLSchema#string

Shiyam Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.

Advances in adjuvant hormonal therapy for postmenopausal women.

Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?

Tamoxifen in breast cancer: not so easy to write off.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

P304

849592

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/849592

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

Asim Jamal Shaikh

P577

2012-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234100151

http://www.w3.org/2001/XMLSchema#string

P698

23304528

http://www.w3.org/2001/XMLSchema#string

P932

3523410

http://www.w3.org/2001/XMLSchema#string